NNC 0194 0499Alternative Names: NN9499; NNC-0194-0499
Latest Information Update: 01 Feb 2017
At a glance
- Originator Novo Nordisk
- Class Obesity therapies
- Mechanism of Action Fibroblast growth factor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
Most Recent Events
- 01 Jan 2017 Phase-I clinical trials in Obesity in USA (SC) (NCT03015207)